Advances in the treatment of HIV and chronic hepatitis C virus infection: A report from the 20th conference on retroviruses and opportunistic infections (croi 2013)

S. A. Rizza, N. Cummins, W. El Atrouni, A. D. Badley, A. Dababneh, Z. Temesgen

Research output: Contribution to journalArticlepeer-review

Abstract

A number of direct-acting agents in advanced clinical development are poised to usher the era of combination treatment against chronic hepatitis C with regimens consisting of solely orally administered drugs. Preliminary data indicate that these drugs are very effective and more tolerable than the traditional interferon and ribavirin combination regimens. The armamentarium of antiretroviral drugs for clinical use continues to expand, albeit at a slower pace than in previous years. However, functional cure of HIV with very early initiation of antiretroviral therapy in an infant and several adolescents has been reported and has further energized the efforts to find a cure for HIV infection.

Original languageEnglish (US)
Pages (from-to)325-333
Number of pages9
JournalDrugs of the Future
Volume38
Issue number5
DOIs
StatePublished - May 2013

Keywords

  • Antiretroviral drugs
  • Chronic hepatitis C
  • HCV entry inhibitors
  • HIV
  • Protease inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Advances in the treatment of HIV and chronic hepatitis C virus infection: A report from the 20th conference on retroviruses and opportunistic infections (croi 2013)'. Together they form a unique fingerprint.

Cite this